1. Home
  2. WRN vs VNDA Comparison

WRN vs VNDA Comparison

Compare WRN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WRN
  • VNDA
  • Stock Information
  • Founded
  • WRN 2006
  • VNDA 2002
  • Country
  • WRN Canada
  • VNDA United States
  • Employees
  • WRN N/A
  • VNDA N/A
  • Industry
  • WRN Metal Mining
  • VNDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • WRN Basic Materials
  • VNDA Health Care
  • Exchange
  • WRN Nasdaq
  • VNDA Nasdaq
  • Market Cap
  • WRN 226.0M
  • VNDA 237.9M
  • IPO Year
  • WRN N/A
  • VNDA 2006
  • Fundamental
  • Price
  • WRN $1.16
  • VNDA $3.95
  • Analyst Decision
  • WRN Strong Buy
  • VNDA Strong Buy
  • Analyst Count
  • WRN 1
  • VNDA 2
  • Target Price
  • WRN $4.25
  • VNDA $16.50
  • AVG Volume (30 Days)
  • WRN 384.5K
  • VNDA 471.1K
  • Earning Date
  • WRN 05-20-2025
  • VNDA 05-07-2025
  • Dividend Yield
  • WRN N/A
  • VNDA N/A
  • EPS Growth
  • WRN N/A
  • VNDA N/A
  • EPS
  • WRN N/A
  • VNDA N/A
  • Revenue
  • WRN N/A
  • VNDA $201,351,000.00
  • Revenue This Year
  • WRN N/A
  • VNDA $14.36
  • Revenue Next Year
  • WRN N/A
  • VNDA $44.53
  • P/E Ratio
  • WRN N/A
  • VNDA N/A
  • Revenue Growth
  • WRN N/A
  • VNDA 13.37
  • 52 Week Low
  • WRN $0.90
  • VNDA $3.85
  • 52 Week High
  • WRN $1.66
  • VNDA $6.75
  • Technical
  • Relative Strength Index (RSI)
  • WRN 53.85
  • VNDA 33.16
  • Support Level
  • WRN $1.09
  • VNDA $4.20
  • Resistance Level
  • WRN $1.20
  • VNDA $4.51
  • Average True Range (ATR)
  • WRN 0.05
  • VNDA 0.18
  • MACD
  • WRN 0.00
  • VNDA -0.02
  • Stochastic Oscillator
  • WRN 65.46
  • VNDA 1.43

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: